tiprankstipranks
AnaptysBio ‘encouraged’ by GSK phase 3 trial results
The Fly

AnaptysBio ‘encouraged’ by GSK phase 3 trial results

AnaptysBio (ANAB) announced that GSK (GSK) has shared interim results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial investigating Jemperli (dostarlimab-gxly) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by dostarlimab-gxly alone compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometrial cancer. These data from GSK’s RUBY clinical trial are being shared in a European Society for Medical Oncology (ESMO) Virtual Plenary, presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer (25-28 March) in Tampa, Florida and published simultaneously in The New England Journal of Medicine. "We continue to be encouraged in the differentiated outcomes delivered by immuno-oncology antibodies discovered at AnaptysBio as GSK advances their development to treat multiple advanced solid tumors. The positive results from the RUBY trial represent a potential breakthrough for patients with primary advanced or recurrent endometrial cancer," said Daniel Faga, interim president and chief executive officer of AnaptysBio. "There is a potential significant royalty opportunity over time to AnaptysBio from Jemperli if this indication is approved, as well as from GSK’s ongoing Phase 3 trials, including of dostarlimab in first line ovarian cancer and, in combination with cobolimab, a TIM-3 antagonist, in second line NSCLC."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on ANAB:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles